Company profile
Sanofi
Pipeline11 assets
- amlitelimabOX40L / Monoclonal antibody / ImmunologyAtopic dermatitisPhase 3ActiveGlobal
- tolebrutinibBTK / Small molecule / NeurologyMultiple sclerosisRegistrationActiveGlobalUS
- lunsekimigBiologic / Immunology and InflammationAsthma / Respiratory diseasesPhase 2ActiveGlobal
- rilzabrutinibBTK / Small molecule / Rare Blood Disorders / ImmunologySickle cell diseasePhase 2/3ActiveGlobalIgG4-related diseasePhase 3ActiveGlobalAsthmaPhase 2ActiveGlobal
- venglustatSmall molecule / Rare DiseasesGaucher disease type 3 (GD3)Phase 3ActiveGlobal
- frexalimabCD40L / Monoclonal antibody / ImmunologyMultiple sclerosisPhase 3ActiveGlobal
- SAR441566SAR441566 / TNFR1si / Small molecule / ImmunologyImmunological diseasesPhase 2ActiveGlobal
- duvakitugTL1A / Monoclonal antibody / ImmunologyUlcerative colitisPhase 2ActiveGlobalCrohn's diseasePhase 2ActiveGlobal
- itepekimabIL-33 / Monoclonal antibody / Immunology and InflammationCOPDPhase 3ActiveGlobal
- isatuximabSarclisa / CD38 / Monoclonal antibody / OncologyMultiple myeloma (subcutaneous)RegistrationActiveEU
- acoziboroleSmall molecule / Infectious DiseasesSleeping sicknessRegistrationActiveAfricaEU
Latest news8 items
All newsATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
Presentation / Abstract • Phase 2ATS presentation Mon, May 18, 2026
DDW: Sanofi and Regeneron’s DUPIXENT® demonstrates improved esophageal function in eosinophilic esophagitis phase 4 study
Presentation / Abstract • Phase 4